Trial Profile

A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta Trap (M7824 ) Alone and in Combination With TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bintrafusp alfa (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Nogapendekin alfa inbakicept (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use

10 Mar 2025 Results (n=6) with no pathologic complete responses were published in the Oncologist
16 Jun 2023 Status changed from active, no longer recruiting to completed.
15 Sep 2022 Results published in the Journal of Clinical Investigation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com